The
antiviral efficacy of
WIN 54954 was demonstrated in vivo in a Coxsackie
B 3 virus (Woodruff strain) induced
myocarditis mouse model. The model was selected because of the high mortality rate during the first week, which was convenient for
antiviral therapy regimen studies. The
antiviral component
WIN 54954 was found to inhibit the early virus-induced mortality almost completely if treatment was started at the same time as virus was inoculated. However, there was still a late mortality, occurring at 1-2 months after virus inoculation. Non-infected mice which were treated with the
drug did not show any such late effects. However,
drug treatment in non-infected mice did not cause any mortality. When
therapy was delayed for one day, 85% survived for 3 weeks as compared to 100% mortality after just over 3 weeks in the infected control group (p < 0.05). With a delay of 4 days after viral inoculation, a
therapeutic effect was still noted. Thus, mortality was virtually abrogated when the compound was given early, but the effect vanished with time of delay. Different preparations of the
WIN 54954 substance were tried, and it was found that a fat
emulsion containing several nutrients (Nutrodrip) was superior to other used formulations. We conclude that the use of the
antiviral drug WIN 54954 in treatment of enteroviral associated diseases is of great value if
therapy is started early. Thus
therapy is almost fully effective within 24 hours of
infection, but the beneficial effects decline with time. Nutrodrip oil
emulsion was found superior as vehicle as compared to other formulations.(ABSTRACT TRUNCATED AT 250 WORDS)